Skip to main content
SpringerLink
Log in

Treat anticoagulant-associated bleeding on the basis of bleeding severity and the availability of reversal agents

  • Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Bleeding is a serious complication associated with the use of both conventional and new anticoagulants in the prevention and treatment of thromboembolic complications. Although bleeding can often be managed with general measures, rapid reversal of the anticoagulant effect through the use of specific antidotes or other interventions is desirable in many cases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Donadini MP, Ageno W, Douketis JD. Management of bleeding in patients receiving conventional or new anticoagulants: a practical and case-based approach. Drugs. 2012;72(15):1965–75.

    Article  PubMed  CAS  Google Scholar 

  2. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3:692–4.

    Article  PubMed  CAS  Google Scholar 

  3. Ost D, Tepper J, Mihara H, et al. Duration of anticoagulation following venous thromboembolism: a meta-analysis. JAMA. 2005;294:76–715.

    Google Scholar 

  4. Palareti G, Leali N, Coccheri S, et al. Bleeding complication of anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Lancet. 1996;348:423–8.

    Article  PubMed  CAS  Google Scholar 

  5. Schulman S, Beyth RJ, Kearon C, et al. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133(6 Suppl):257S–98S.

    Article  PubMed  CAS  Google Scholar 

  6. Garcia DA, Baglin TP, Weitz JI, et al. Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th edition: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e24S–43S.

    Article  PubMed  CAS  Google Scholar 

  7. Bianchini EP, Fazavana J, Picard V, et al. Development of a recombinant antithrombin variant as a potent antidote to fondaparinux and other heparin derivatives. Blood. 2011;117:2054–60.

    Article  PubMed  CAS  Google Scholar 

  8. Desmurs-Clavel H, Huchon C, Chatard B, et al. Reversal of the inhibitory effect of fondaparinux on thrombin generation by rFVIIa, aPCC and PCC. Thromb Res. 2009;123:796–8.

    Article  PubMed  CAS  Google Scholar 

  9. Bijsterveld NR, Vink R, van Aken BE, et al. Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers. Br J Haematol. 2004;124:653–8.

    Article  PubMed  CAS  Google Scholar 

  10. Bijsterveld NR, Moons AH, Boekholdt SM, et al. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation. 2002;106:2550–4.

    Article  PubMed  CAS  Google Scholar 

  11. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51.

    Article  PubMed  CAS  Google Scholar 

  12. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–91.

    Article  PubMed  CAS  Google Scholar 

  13. Kaatz S, Kouides PA, Garcia DA, et al. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol. 2012;97(Suppl 1):S141–5.

    Article  Google Scholar 

  14. Eerenberg ES, Kamphuisen PW, Sijpkens MK, et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011;124:1573–9.

    Article  PubMed  CAS  Google Scholar 

  15. Marlu R, Hodaj E, Paris A, et al. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost. 2012;108(2):217–24.

    Article  PubMed  CAS  Google Scholar 

  16. Stangier J, Rathgen K, Stahle H, et al. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet. 2010;49:259–68.

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosure

This review was adapted from Drugs 2012;72(15):1965–75 [1]. The preparation of these articles was not supported by any external funding.

Author information

Authors and Affiliations

    Consortia

    Adis Medical Writers

    Rights and permissions

    Reprints and permissions

    About this article

    Cite this article

    Adis Medical Writers. Treat anticoagulant-associated bleeding on the basis of bleeding severity and the availability of reversal agents. Drugs Ther Perspect 29, 77–81 (2013). https://doi.org/10.1007/s40267-012-0010-z

    Download citation

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s40267-012-0010-z

    Keywords

    Search

    Navigation